Healing chronic infected foot wounds with human fibroblast-derived dermal substitute and silver dressings

Wounds

Volumn 17, Issue 10, 2005, Pages 282-289

  Carson, Stanley N ^a,b   Pankovich, Alanna ^a   Travis, Eric ^a   To, Diana ^a   Rodriguez, Angie ^a  

^a Fountain Valley Regional Hospital and Medical Center   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 28144445113     PISSN: 10447946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Laing P. The development and complications of diabetic foot ulcers. Am J Surg. 1998;176(2A Suppl):11S-19S.
2. Marston WA, Hanft J, Norwood P, Pollak R; Dermagraft Diabetic Foot Ulcer Study Group. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care. 2003;26(6):1701-1705.
3. Reiber GE, Lipsky BA, Gibbons GW. The burden of diabetic foot ulcers. Am J Surg. 1998;176(2A Suppl):5S-10S.
4. Consensus Development Conference on Diabetic Foot Wound Care: 7-8 April 1999, Boston, Massachusetts. American Diabetes Association. Diabetes Care. 1999;22(8):1354-1360.
5. Rich J, Veves A. Forefoot and rearfoot plantar pressures in diabetic patients: correlation to foot ulceration. WOUNDS. 2000;12(4):82-87.
6. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers: a phase III randomized placebo-controlled double-blind study. Diabetes Care. 1998;21(5):822-827.
7. McNeely MJ, Boyko EJ, Ahroni JH, et al. The independent contributions of diabetic neuropathy and vasculopathy in foot ulceration. How great are the risks? Diabetes Care. 1995;18(2):216-219.
8. Nehler MR, Hiatt WR, Taylor LM Jr. Is revascularization and limb salvage always the best treatment for critical limb ischemia? J Vasc Surg. 2003;37(3):704-707.
9. Kalani M, Brismar K, Fagrell B, Ostergren J, Jorneskog G. Transcutaneous oxygen tension and toe blood pressure as predictors for outcome of diabetic foot ulcers. Diabetes Care. 1999;22(1):147-151.
10. Carson SN, Overall K. Adjunctive therapy for ischemic wounds using cilostazol. WOUNDS. 2003;15(3):77-82.
11. Frykberg RG, Armstrong DG, Giurini J, et al. Diabetic Foot Disorders: A Clinical Practice Guideline. Brooklandville, Md: Data Trace Publishing Co, 2000.
12. Gentzkow GD, Jensen JL, Pollock RA, et al. Improved healing of diabetic foot ulcers after grafting with a living human dermal replacement. WOUNDS. 1999;11(3):77-84.
13. Robson MC, Steed DL, McPherson JM, Pratt BM. Use of transforming growth factor beta 2 (TGF-beta2) in the treatment of chronic foot ulcers in diabetic patients. Wound Repair Regen. 1999;7(4):A266.
14. Wu L, Xia YP, Roth SI, Gruskin E, Mustoe TA. Transforming growth factor-beta1 fails to stimulate wound healing and impairs its signal transduction in an aged ischemic ulcer model: importance of oxygen and age. Am J Pathol. 1999;154(1):301-309.
15. APhA drug treatment protocols: management of foot ulcers in patients with diabetes. J Am Pharm Assoc. 2000;40(4):467-474.
16. McGuckin M, Stineman MG, Goin JE, Williams SV. Venous Leg Ulcer Guideline. Wayne, Pa: Health Management Publications Inc.; 1997.
17. Bergstrom N, Allman RM, Alvarez OM, et al. Clinical Practice Guideline Number 15: Treatment of Pressure Ulcers. Rockville, Md: US Department of Health and Human Services. Agency for Health Care Policy and Research; 1994. AHCPR Publication No. 95-0652.
18. Littman GS, Walker BR, Schneider BE. Reassessment of verbal and visual analog ratings in analgesic studies. Clin Pharmacol Ther. 1985;38(1):16-23.
19. Stotts NA. Determination of bacterial burden in wounds. Adv Wound Care. 1995;8(4):46-52.
20. Eisenbud D, Huang NF, Luke S, Silberklang M. Skin substitutes and wound healing: current status and challenges. WOUNDS. 2004;16(1):2-17.
21. Mulder G, Armstrong D, Seaman S. Standard, appropriate, and advanced care and medical-legal considerations: part one-diabetic foot ulcerations. WOUNDS. 2003;15(4):92-106.
22. Volpato S, Blaum C, Resnick H, Ferrucci L, Fried LP, Guralnik JM; Women's Health and Aging Study. Comorbidities and impairments explaining the association between diabetes and lower extremity disability: The Women's Health and Aging Study. Diabetes Care. 2002;25(4):678-683.
23. Lodise TP, McKinnon PS, Tam VH, Rybak MJ. Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center. Clin Infect Dis. 2002;34(7):922-929.
24. Velmahos GC, Toutouzas KG, Sarkisyan G, et al. Severe trauma is not an excuse for prolonged antibiotic prophylaxis. Arch Surg. 2002;137(5):537-541; discussion 541-542.
25. Thomas S, McCubbin P. A comparison of the antimicrobial effects of four silver-containing dressings on three organisms. J Wound Care. 2003;12(3):101-107.
26. Demling RH, DeSanti L. The rate of re-epithelialization across meshed skin grafts is increased with exposure to silver. Burns. 2002;28(3):264-266.
27. Wilson V. Assessment and management of fungating wounds: a review. Br J Community Nurs. 2005;10(3):S28-34.